Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gastroesophageal reflux disease, use of H-2 receptor antagonists, and riskof esophageal and gastric cancer
Autore:
Farrow, DC; Vaughan, TL; Sweeney, C; Gammon, MD; Chow, WH; Risch, HA; Stanford, JL; Hansten, PD; Mayne, ST; Schoenberg, JB; Rotterdam, H; Ahsan, H; West, AB; Dubrow, R; Fraumeni, JF; Blot, WJ;
Indirizzi:
Univ Washington, Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle,WA 98109 USA Univ Washington Seattle WA USA 98109 gram Epidemiol, Seattle,WA 98109 USA Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98109 USA Univ Washington Seattle WA USA 98109 ept Epidemiol, Seattle, WA 98109 USA Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Epidemiol, New York, NYUSA Columbia Univ New York NY USA Publ Hlth, Div Epidemiol, New York, NYUSA NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA NCI Bethesda MD USANCI, Div Canc Epidemiol & Genet, Bethesda, MD USA Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA Yale Univ New Haven CT USA 06510 iol & Publ Hlth, New Haven, CT 06510 USA Univ Washington, Dept Pharm, Seattle, WA 98195 USA Univ Washington Seattle WA USA 98195 n, Dept Pharm, Seattle, WA 98195 USA New Jersey Dept Hlth & Senior Serv, Off Canc Epidemiol, Trenton, NJ USA New Jersey Dept Hlth & Senior Serv Trenton NJ USA emiol, Trenton, NJ USA Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA Columbia Univ New York NY USA Phys & Surg, Dept Pathol, New York, NY USA Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA Yale Univ New Haven CT USA 06520 ed, Dept Pathol, New Haven, CT 06520 USA Int Epidemiol Inst, Rockville, MD USA Int Epidemiol Inst Rockville MD USA nt Epidemiol Inst, Rockville, MD USA
Titolo Testata:
CANCER CAUSES & CONTROL
fascicolo: 3, volume: 11, anno: 2000,
pagine: 231 - 238
SICI:
0957-5243(200003)11:3<231:GRDUOH>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
HISTAMINE-2-RECEPTOR ANTAGONISTS; RISING INCIDENCE; UNITED-STATES; ADENOCARCINOMA; CARDIA; CIMETIDINE; ALCOHOL; TOBACCO; DRUGS; CARCINOMA;
Keywords:
esophageal neoplasms; gastric neoplasms; gastroesophageal reflux disease; H-2 receptor antagonists;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Farrow, DC Univ Washington, Fred Hutchinson Canc Res Ctr, Program Epidemiol, 1100 Fairview Ave N,POB 19024,MP-474, Seattle, WA 98109 USA Univ Washington 1100 Fairview Ave N,POB 19024,MP-474 Seattle WA USA 98109
Citazione:
D.C. Farrow et al., "Gastroesophageal reflux disease, use of H-2 receptor antagonists, and riskof esophageal and gastric cancer", CANC CAUSE, 11(3), 2000, pp. 231-238

Abstract

Objective: The incidence of esophageal adenocarcinoma has risen rapidly inthe past two decades, for unknown reasons. The goal of this analysis was to determine whether gastroesophageal reflux disease (GERD) or the medications used to treat it are associated with an increased risk of esophageal or gastric cancer, using data from a large population-based case-control study. Methods: Cases were aged 30-79 years, newly diagnosed with esophageal adenocarcinoma (n = 293), esophageal squamous cell carcinoma (n = 221), gastriccardia adenocarcinoma (n = 261), or non-cardia gastric adenocarcinoma (n =368) in three areas with population-based tumor registries. Controls (n = 695) were chosen by random digit dialing and from Health Care Financing Administration rosters. Data were collected using an in-person structured interview. Results: History of gastric ulcer was associated with an increased risk ofnon-cardia gastric adenocarcinoma (OR 2.1, 95% CI 1.4-3.2). Risk of esophageal adenocarcinoma increased with frequency of GERD symptoms; the odds ratio in those reporting daily symptoms was 5.5 (95% CI 3.2-9.3). Ever having used H-2 blockers was unassociated with esophageal adenocarcinoma risk (OR 0.9, 95% CI 0.5-1.5). The odds ratio was 1.3 (95% CI 0.6-2.8) in long-term (4 or more years) users, but increased to 2.1 (95% CI 0.8-5.6) when use in the 5 years prior to the interview was disregarded. Risk was also modestly increased among users of antacids. Neither GERD symptoms nor use of H-2 blockers or antacids was associated with risk of the other three tumor types. Conclusions: Individuals with long-standing GERD are at increased risk of esophageal adenocarcinoma, whether or not the symptoms are treated with H-2blockers or antacids.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 21:26:37